HeimSGIOY • OTCMKTS
Shionogi 4 ADR Representing Ord Shs
11,12 $
Eftir lokun
11,12 $
(0,00%)0,00
Lokað: 27. sep., 16:13:27 GMT-4 · USD · OTCMKTS · Lagalegir fyrirvarar
GLeaf-lógóLoftslagsleiðtogiSkráð hlutabréf í BandaríkinHöfuðstöðvar: JP
Við síðustu lokun
11,24 $
Dagbil
10,51 $ - 11,23 $
Árabil
9,33 $ - 13,67 $
Markaðsvirði
1,90 bn JPY
Meðalmagn
42,60 þ.
CDP-loftslagseinkunn
A
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(JPY)jún. 2024Breyting á/á
Tekjur
97,59 ma.-10,73%
Rekstrarkostnaður
55,03 ma.10,94%
Nettótekjur
30,64 ma.-28,02%
Hagnaðarhlutfall
31,39-19,39%
Hagnaður á hvern hlut
EBITDA
33,03 ma.-35,20%
Virkt skatthlutfall
17,02%
Heildareignir
Heildarskuldir
(JPY)jún. 2024Breyting á/á
Reiðufé og skammtímafjárfestingar
281,96 ma.-2,46%
Heildareignir
1,45 bn6,23%
Heildarskuldir
157,74 ma.-8,07%
Eigið fé alls
1,29 bn
Útistandandi hlutabréf
283,49 m.
Eiginfjárgengi
0,00
Arðsemi eigna
4,90%
Ávöxtun eigin fjár
5,48%
Breyting á handbæru fé
(JPY)jún. 2024Breyting á/á
Nettótekjur
30,64 ma.-28,02%
Handbært fé frá rekstri
33,50 ma.6,74%
Reiðufé frá fjárfestingum
-90,85 ma.-161,40%
Reiðufé frá fjármögnun
-24,83 ma.-7,63%
Breyting á handbæru fé
-76,13 ma.-277,88%
Frjálst peningaflæði
-81,81 ma.-634,02%
Um
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Framkvæmdastjóri
Stofnsett
17. mar. 1878
Höfuðstöðvar
Vefsvæði
Starfsfólk
4.959
Leit
Hreinsa leit
Loka leit
Google forrit
Aðalvalmynd